This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UROV Urovant Sciences (UROV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Urovant Sciences Stock (NASDAQ:UROV) 30 days 90 days 365 days Advanced Chart Get Urovant Sciences alerts:Sign Up Key Stats Today's Range$16.24▼$16.2450-Day Range$16.19▼$16.2452-Week Range$7.15▼$16.26VolumeN/AAverage Volume114,469 shsMarket Capitalization$531.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Read More Receive UROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address UROV Stock News HeadlinesRoivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation RiddleJuly 5, 2025 | seekingalpha.comXavier Creative House Appoints Jami Rogers as VP of Sales & MarketingNovember 4, 2024 | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 18 at 2:00 AM | Brownstone Research (Ad)Xavier Creative House Hires Jami Rogers as Vice President of Sales & MarketingOctober 29, 2024 | finance.yahoo.comPierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromeApril 26, 2024 | finanznachrichten.dePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromeApril 26, 2024 | finance.yahoo.comA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsMarch 26, 2024 | finance.yahoo.comPetauri™ Elects William Fleming and James Robinson to Its Board of DirectorsDecember 6, 2023 | finance.yahoo.comSee More Headlines UROV Stock Analysis - Frequently Asked Questions How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd. (NASDAQ:UROV) issued its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.59) by $0.13. When did Urovant Sciences IPO? Urovant Sciences (UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO). Company Calendar Last Earnings2/11/2021Today7/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UROV CIK1740547 Webwww.urovant.com Phone44-0-20-7400-3347FaxN/AEmployees70Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.74 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.90% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-8.55Miscellaneous Outstanding Shares32,743,000Free FloatN/AMarket Cap$531.75 million OptionableNot Optionable Beta2.36 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:UROV) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored“All the land that you see I will give to you and your offspring forever…”“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Urovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.